Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status
- PMID: 37984801
- DOI: 10.1016/j.bbadis.2023.166962
Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status
Abstract
Oncolytic viruses (OVs) are emerging as therapeutically relevant anticancer agents as contemporary immunotherapy gains traction. Furthermore, OVs are an ideal platform for genetic modification to express therapeutic transgenes. Bispecific T cell engagers (BiTEs) can redirect T cells to tumor cells, resulting in targeted cytotoxicity. BiTEs have demonstrated success in hematological cancers but are rarely used in solid tumors. The drawbacks of BiTEs, including inadequate delivery and on-target-off-tumor activity have limited their efficacy. Combining OVs with BiTEs is a prospective area to investigate. This combined strategy can benefit from the best qualities of both therapies while overcoming the limitations.
Keywords: Bispecific T cell engagers; Combination therapy; Immunotherapy; Oncolytic viruses.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700187. Epub 2017 Sep 13. Macromol Biosci. 2018. PMID: 28902983 Review.
-
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.J Hematol Oncol. 2021 Apr 16;14(1):63. doi: 10.1186/s13045-021-01075-5. J Hematol Oncol. 2021. PMID: 33863363 Free PMC article. Review.
-
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.Front Immunol. 2024 Feb 22;15:1343378. doi: 10.3389/fimmu.2024.1343378. eCollection 2024. Front Immunol. 2024. PMID: 38464532 Free PMC article. Review.
-
Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.Stem Cells. 2019 Jun;37(6):716-723. doi: 10.1002/stem.3004. Epub 2019 Apr 9. Stem Cells. 2019. PMID: 30875126 Review.
-
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.Clin Cancer Res. 2018 May 1;24(9):2128-2137. doi: 10.1158/1078-0432.CCR-17-2651. Epub 2018 Feb 6. Clin Cancer Res. 2018. PMID: 29437789
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources